HHS Opens Door for Small Pharmacies to Make Six Unapproved Peptides

Patients seeking wellness peptides will soon have a clearer path to purchase them through local pharmacies. The Department of Health and Human Services announced a new policy that grants enforcement discretion for six specific peptides. This move allows small compounding pharmacies to manufacture these substances without facing immediate federal action, even though the compounds have not received formal approval from the Food and Drug Administration.

The policy targets six specific amino acid chains: BPC-157 for ulcerative colitis, Epitalon for insomnia, KPV for wound healing, MOTS-c for metabolic health, Semax for migraine, and TB-500 for wound healing. These substances have long been sold in a gray market, often labeled as research use only and sourced from overseas suppliers. HHS argues that compounding provides a safer alternative to these unregulated imports by subjecting production to pharmacy standards and adverse event reporting.

Health Secretary Robert F. Kennedy Jr., a vocal supporter of peptide use, has personally used some of these compounds. While the administration frames the move as a way to bring popular treatments into a regulated system, the scope of the policy is narrow. It applies only to 503A compounding pharmacies, which operate at a smaller scale. It does not extend to 503B outsourcing facilities, the larger operations that produce high volumes of medicine for national distribution.

Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, notes that demand for these peptides has been steady for years. His company did not produce them previously because they were illegal to compound under existing rules. Under the new guidance, his smaller facility can begin production, but only in limited quantities. Fritzler expects his company to start with just one of the six peptides and must first prepare its facility for the specific requirements.

Fritzler believes the supply chain may struggle to keep up with consumer interest. He stated that he does not think all the 503A pharmacies in the country could meet the demand. This limitation means that even with the policy change, patients may face shortages or longer wait times as smaller pharmacies ramp up their operations and verify their ingredient suppliers.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, expressed support for the decision in a statement. He said the policy offers a more accountable alternative for patients and brings them into a system with regulatory oversight. However, he warned that it may take time for pharmacies to begin dispensing the products. Suppliers must ensure their active ingredients meet the new policy requirements, and pharmacies must verify that compliance before use.

Consumer advocacy groups have raised concerns about the lack of a standard rulemaking process. Public Citizen, a nonprofit organization, noted that the Secretary appears to have acted unilaterally. Dr. Robert Steinbrook, the group's Health Research Group Director, wrote that the move undermines the FDA and threatens public health by allowing unproven substances to be marketed without concern for federal enforcement. He advised clinicians to inform patients about the risks of contamination and other adverse effects.

The Partnership for Safe Medicines filed a citizen petition with the FDA last week. The group urged the agency to ignore its own advisory committee's July vote in favor of expanded access. Shabbir Safda, the executive director of the partnership, wrote that the decision leaves Americans in a gray area regarding safety. He pointed out that FDA scientists had recommended against unwinding restrictions due to concerns about the evidence base for these compounds.